The level of antibodies against the spike protein coronavirus is one of the main factors influencing survival in COVID-19. Researchers from Spain and Canada, who evaluated three blood tests, came to the relevant conclusions. The results of their study were published Oct. 5 in the Journal of Internal Medicine.
Foci of infection: wood smoke increases chances of contracting the coronavirus
Why the effect is stronger in women
A person's protection against the coronavirus can be judged by three measures - the level of antibodies against certain antigens, the total number of antigens, or the amount of viral RNA in the blood.
For the study, scientists selected data on 92 people who had been hospitalized during the first wave of the coronavirus pandemic. All were diagnosed with COVID-19 by PCR test, and had blood tests taken within the first 24 hours of their hospital stay.
The results showed that only one indicator correlated with a high risk of death - a low antibody response against the SARS-CoV-2 virus S-protein.
"Our results confirm that treatment with exogenous antibodies for COVID-19 should be personalized, and such therapy should be used only for patients with missing or low levels of endogenous antibodies," said Jesus Bermejo-Martin, one of the study authors.
According to the scientists, their study will help determine the level of antibodies optimal for each patient in critical condition.
Earlier, on October 1, an international team of scientists from Germany, Switzerland, USA, Spain, Austria, UK and Russia, led by specialists from Charité clinic (Berlin), found that the owners of a special variant of the gene regulating the functions of the immune system are twice as likely to be put on IVC when infected with coronavirus